Left Main Revascularization Surgical and Interventional Perspectives∗ by Sabik, Joseph F. & Stone, Gregg W.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 2 0 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 4 . 0 0 6EDITORIAL COMMENTLeft Main Revascularization
Surgical and Interventional Perspectives*Joseph F. Sabik, MD,y Gregg W. Stone, MDzSEE PAGE 2198A s physicians, there are few decisions that weare asked to make that are more importantthan how to best manage patients with crit-
ical disease of the left main coronary artery. For
such patients, effective revascularization is essential
to prolong life and preserve health. Soon after its
introduction, coronary artery bypass graft surgery
(CABG) became established as standard of care for
left main disease (LMD). Over the last 3 decades,
this gold standard has been challenged by the steady
advance of the percutaneous coronary intervention
(PCI) technique and technology, with recent clinical
studies suggesting that this lesser invasive approach
may offer real beneﬁts to a selected cohort of LMD pa-
tients. Pending the results from ongoing randomized
trials, what proportion of patients with LMD are
currently appropriately managed with PCI, and how
should they be selected? Assessing the current evi-
dence base to answer these questions requires under-
standing of both the surgical and interventional
perspective. The present editorial presents both
viewpoints to inform the referring physician and
heart team treating today’s patient with LMD.
THE CASE FOR SURGICAL REVASCULARIZATION
OF LMD
Ever since the randomized trials comparing CABG
with medical therapy were performed more than 4
decades ago, CABG has been the standard of care for*Editorials published in the Journal of the American College of Cardiology
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Medtronic and the Sorin Group.LMD. Although only 150 patients with LMD were
randomized, the 3-year mortality in patients under-
going CABG was less than one-third (9% vs. 31%) that
of medically treated patients, and there was a 2-fold
increase (13.3 vs. 6.6 years) in median survival (1–4).
Observational studies found similar beneﬁts of CABG
in patients with LMD (5).In this issue of the Journal, the 5-year results from
the PRECOMBAT (Premier of Randomized Com-
parison of Bypass Surgery Versus Angioplasty Using
Sirolimus-Eluting Stent in Patients With Left Main
Coronary Artery Disease) trial (6) suggest that PCI may
be as effective as CABG for the treatment of selected
patients with LMD. Similarly, the SYNTAX (Synergy
Between PCI With Taxus and Cardiac Surgery) trial
also found that patients with LMD treated with
PCI survived as well as those treated with CABG
(nonsigniﬁcantly different 5-year rates of major ad-
verse cardiovascular and cerebral events [MACCE])
(7). However, comparable outcomes were conﬁned to
those with low or intermediate coronary artery disease
(CAD) complexity (SYNTAX scores #32). Patients with
complex CAD (SYNTAX scores $33) performed better
(lower mortality and MACCE rates) with CABG. Others
have reported similar ﬁndings (8). It should thus not
be surprising that the mean SYNTAX score of the pa-
tients in the PRECOMBAT trial was only 24.4 in the PCI
group and 25.8 in the CABG group.
Although these observations suggest that some
patients with LMD may have acceptable outcomes
with PCI, the majority of patients with LMD have
complex CAD that is best treated with surgery. In a
registry study of patients with LMD undergoing CABG
(predating PCI as therapy for LMD), the majority of
patients had concomitant triple-vessel disease (9).
Only 4% had isolated LMD, 13% had LMD and single-
vessel disease, and 27% had LMD with double-vessel
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2208disease. Low and intermediate SYNTAX scores occur
in patients with isolated LMD and LMD associated
with single-vessel and sometimes double-vessel dis-
ease. High SYNTAX scores in patients with LMD are
found in advanced double-vessel disease and in most
cases of triple-vessel disease (8). In the SYNTAX
surgical registry, the extent of CAD was too complex
for PCI (mean SYNTAX score 37.8) (10). Combining
together the surgical registry with the randomized
LMD with complex CAD cohorts, nearly 60% of pa-
tients enrolled in the SYNTAX trial with LMD were
best treated surgically.
In addition, patients with triple-vessel CAD
(without LMD) in the SYNTAX trial had better out-
comes with CABG than PCI (7), with lower 5-year rates
of mortality, myocardial infarction (MI), and repeat
revascularization. The ﬁnding that patients with
3-vessel CAD have better outcomes with CABG was
recently conﬁrmed in the BEST (Randomized Com-
parison of Coronary Artery Bypass Surgery and
Everolimus-Eluting Stent Implantation in the Treat-
ment of Patients With Multivessel Coronary Artery
Disease) trial, which used contemporary everolimus-
eluting stents in the PCI group (11). Because the ma-
jority of patients with LMD also have 3-vessel CAD,
most patients with LMD will have superior outcomes
with CABG.
Why is CABG a better option for most patients with
LMD? By achieving more complete revascularization
than PCI, CABG is more effective at relieving ischemia;
by bypassing longer segments of atherosclerosis, it
may also pre-emptively exclude vulnerable plaques,
thereby avoiding future clinical events. Incomplete
revascularization after PCI compared with CABG is
especially common in patients with complex CAD (12).
In the large-scale ACUITY (Acute Catheterization
and Urgent Intervention Triage Strategy) trial, only
40% of patients with acute coronary syndromes
treated with PCI had a residual SYNTAX score (RSS) of
zero (complete revascularization), and the majority of
those had low baseline CAD complexity (SYNTAX
scores <22) (13). Only 12% of patients with baseline
SYNTAX scores $22 had a zero RSS after PCI. Higher
RSS was associated with greater composite rates of
death, MI, or need for repeat reintervention. The di-
rect relationship between the extent of ischemia and
adverse outcomes has been well documented (14).
The American College of Cardiology Foundation/
Society for Cardiovascular Angiography and In-
terventions/Society of Thoracic Surgeons/American
Association for Thoracic Surgery/American Heart
Association/American Society of Nuclear Cardiology/
Heart Failure Society of America/Society of Cardio-
vascular Computed Tomography 2012 AppropriateUse Criteria for Coronary Revascularization Focused
Update rated CABG for LMD as appropriate and PCI
for LMD as uncertain or inappropriate, depending on
CAD complexity (15). They are correct; more evidence
is needed before recommending PCI for the treatment
of LMD.
THE (EVOLVING) CASE FOR INTERVENTIONAL
REVASCULARIZATION OF LMD
Although CABG is the historical gold standard for
treatment of LMD, the outcomes of PCI have been
steadily improving and now rival or may have sur-
passed CABG in several scenarios. Even with the ﬁrst-
generation paclitaxel-eluting stents used in the PCI
arm of the SYNTAX trial, the 5-year outcomes of PCI
were equivalent (or even superior, with lower mor-
tality) in the approximate two-thirds of randomized
patients with LMD with low and intermediate CAD
complexity (SYNTAX scores #32) (16). These results
have now been replicated in the present report from
the PRECOMBAT trial, in which the 5-year composite
rate of major adverse cardiac events (death, MI, or
stroke) were not signiﬁcantly different between ﬁrst-
generation sirolimus-eluting stents and CABG in LMD
(6). Clinical characteristics may also differentiate pa-
tients likely to beneﬁt from PCI rather than CABG,
even in those with extensive CAD (17). And PCI results
in lower rates of total and disabling stroke than CABG,
an important consideration in patients with LMD in
whom the perioperative stroke risk is increased (18).
After mortality, stroke is the most feared complica-
tion of major surgery. This fact, coupled with the
lesser invasive nature of PCI with improved early
quality of life and faster return to normal activities
than with CABG (19), makes PCI an attractive alter-
native to major surgery for most patients as long as
the long-term outcomes are not prohibitively worse.
Such patient-centered decision-making must be
strongly considered when discussing revasculariza-
tion options.
Importantly, the results of PCI in LMD are steadily
improving over time. Several nonrandomized studies
have suggested that current-generation everolimus-
eluting stents result in improved outcomes in LMD
compared with ﬁrst-generation drug-eluting stents
(DES) (20,21). At the Asan Medical Center in Seoul,
Korea, the transition to contemporary DES, coupled
with improvements in interventional technique, im-
aging, physiological lesion assessment, and pharma-
cotherapy, has resulted in steady improvements in
PCI outcomes for multivessel disease over a 15-year
period (despite increasingly complex patient and
lesion characteristics), whereas the results of CABG
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following PCI have now matched or exceeded those
following CABG at this high-volume institution,
which accordingly has been associated with a greater
proportion of patients referred to PCI over time.
Although PCI with even the best DES is likely to result
in somewhat higher rates of repeat revascularization
procedures than CABG in patients with complex CAD,
this contingency represents an acceptable trade-off
for many patients, given the other attributes of the
lesser invasive approach.
In this regard, achieving reasonably complete
revascularization is important in patients with CAD,
and CABG should be favored in patients in whom PCI
is likely to result in a high RSS (e.g., >8). CABG is thus
likely to remain the preferred approach in patients
with extremely advanced CAD, although this gap is
narrowing, given advances with PCI techniques in
chronic total occlusions and other complex anato-
mies. Moreover, achieving functional revasculariza-
tion of all ischemic territories may be superior to
complete anatomic revascularization (23), the topic
of the ongoing FAME 3 (Fractional Flow Reserve
Versus Angiography for Multivessel Evaluation 3)
randomized trial (NCT02100722). Success rates of PCI
for complex CAD are also operator and site dependent
(as is true for CABG), a sometimes uncomfortable factthat must be acknowledged when revascularization
referral decisions are made.
Ultimately, whether PCI with contemporary de-
vices and techniques is equal or superior to CABG
for selected patients with LMD rests on the results
from adequately powered randomized trials. In this
regard, 2 ongoing studies, the EXCEL (Evaluation
of XIENCE PRIME Everolimus-Eluting Stent Sys-
tem [EECSS] or XIENCE V EECSS Versus Coro-
nary Artery Bypass Surgery for Effectiveness of Left
Main Revascularization; NCT01205776) and NOBLE
(Nordic-Baltic-British Left Main Revascularization;
NCT01496651) trials have completed randomizing
more than 3,100 patients with LMD and simple to
moderately complex concomitant CAD to contempo-
rary DES versus CABG. The outcomes from these tri-
als, expected in the fall of 2016, will importantly
shape the perspectives expressed in this present
editorial—at least until the next major advances in
interventional and surgical revascularization are
realized!
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